The efficacy of influenza vaccination in a pediatric oncology population

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 5, 2010, Pages e177-e181

  Reilly, Anne ^a   Kersun, Leslie S ^a   McDonald, Kenyetta ^a   Weinberg, Adriana ^a   Jawad, Abbas F ^b   Sullivan, Kathleen E ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Antibody; Chemotherapy; Influenza; Seroconversion; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IFOSFAMIDE; INFLUENZA VACCINE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TIOGUANINE; VINCRISTINE; INACTIVATED VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY TITER; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ONCOLOGY; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SARCOMA; SCHOOL CHILD; SEROCONVERSION; SEROTYPE; TREATMENT OUTCOME; TREATMENT RESPONSE; IMMUNOLOGY; INFLUENZA VIRUS A; VACCINATION;

ANTINEOPLASTIC AGENTS; CHILD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SARCOMA; TREATMENT OUTCOME; VACCINATION; VACCINES, INACTIVATED;

EID: 77955916833     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181d869f3     Document Type: Article

References (23)

1. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) [erratum appears in MMWR Recomm Re. 20 August, 2004; 53(32): 743]. MMWR Recomm Rep. 2004; 53: 1-40.
2. Hicks KL, Chemaly RF, Kontoyiannis DP. Common community respiratory viruses in patients with cancer: more than just “common colds.” Cancer. 2003; 97: 2576-2587.
3. Kempe A, Hall CB, MacDonald NE, et al. Influenza in children with cancer. J Pediatr. 1989; 115: 33-39.
4. Strikas RA, Wallace GS, Myers MG. Influenza pandemic preparedness action plan for the United States: 2002 update. Clin Infect Dis. 2002; 35: 590-596.
5. Chisholm JC, Devine T, Charlett A, et al. Response to influenza immunisation during treatment for cancer. Arch Dis Child. 2001; 84: 496-500.
6. Centkowski P, Brydak L, Machala M, et al. Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J Clin Immunol. 2007; 27: 339-346.
7. Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res. 2005; 3: 214-220.
8. Avritscher EB, Cooksley CD, Geraci JM, et al. Cost-effectiveness of influenza vaccination in working-age cancer patients. Cancer. 2007; 109: 2357-2364.
9. Nordoy T, Aaberge IS, Husebekk A, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol. 2002; 19: 71-78.
10. Tasian SK, Park JR, Martin ET, et al. Influenza-associated morbidity in children with cancer. Pediatr Blood Cancer. 2008; 50: 983-987.
11. Potter MN, Foot AB, Oakhill A. Influenza A and the virus associated haemophagocytic syndrome: cluster of three cases in children with acute leukaemia. J Clin Pathol. 1991; 44: 297-299.
12. Klimov AI, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis. 1995; 172: 1352-1355.
13. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003; 348: 867-868.
14. Kroger AT, Atkinson WL, Marcuse EK, et al. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55: 1-48.
15. Patel SR, Chisholm JC, Heath PT. Vaccinations in children treated with standard-dose cancer therapy or hematopoietic stem cell transplantation. Pediatr Clin N Am. 2008; 55: 169-186.
16. Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev. 2009;CD006484.
17. Chisholm J, Howe K, Taj M, et al. Influenza immunisation in children with solid tumours. Eur J Cancer. 2005; 41: 2280-2287.
18. Bektas O, Karadeniz C, Oguz A, et al. Assessment of the immune response to trivalent split influenza vaccine in children with solid tumors. Pediatr Blood Cancer. 2007; 49: 914-917.
19. Steinherz PG, Brown AE, Gross PA, et al. Influenza immunization of children with neoplastic diseases. Cancer. 1980; 45: 750-756.
20. Levin MJ, Song LY, Fenton T, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008; 26: 4210-4217.
21. Cooksley CD, Avritscher EB, Bekele BN, et al. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer. 2005; 104: 618-628.
22. Baz M, Abed Y, McDonald J, et al. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006; 43: 1555-1561.
23. Loulergue P, Mir O, Alexandre J, et al. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol. 2008; 19: 1658.